PP16 Metronomic weekly use of zoledronic acid for breast cancer with bone metastases has more potent antitumor and bone-preserving effects than conventional zoledronic acid given every-four-weeks

✍ Scribed by X. Hu; X. Zhao; X. Xu; J. Ragaz; H. Guo; J. Wu; Z. Shao; X. Guo; J. Chen; Z. Wang

• Book ID: 119600911
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 64 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(09)72171-8